Jason Ryan

Chairman of the Board

Jason Ryan is Chairman of GeneDx’s Board of Directors. Jason held this same role at Sema4 prior to the company being renamed to GeneDx in January 2023. Jason began serving on Sema4’s Board of Directors in July 2021 and assumed the role of Executive Chair six months later.

Jason has held numerous executive leadership and board roles in diagnostics and therapeutics companies, with broad experience in scaling businesses from early stage through product launch and commercialization.

Jason most recently served as COO and CFO of Magenta Therapeutics (Nasdaq: MGTA), a company focused on developing novel medicines for patients with autoimmune diseases and blood cancers. Prior to that, Jason was CFO of Foundation Medicine, a transformative company in oncology molecular profiling. He helped lead that business through early development, its initial public offering, subsequent growth into a global commercial organization and ultimately, its acquisition by Roche Holdings (Nasdaq: RHHBY). Before Foundation Medicine, Jason led the finance and strategic planning efforts of several other high growth life science companies.

In addition to GeneDx, Jason currently serves on the board of directors of Singular Genomics (Nasdaq: OMIC) and previously served on the board of directors of ArcherDX, Inc. (acquired by Invitae Corporation (NYSE: NVTA)).

He began his career at Deloitte & Touche, where he earned a CPA, and he received a BA in Economics from Bates College and an MBA from Babson College.